Interview with Frederic Dufour, General Manager, Biocodex Russia
You have been at your current position for less than a year, and joined BIOCODEX after having managed the Russian affiliate of Yves Saint Laurent. You have a long history…
Address: 119019, г. Москва, ул. Новый Арбат д. 21,Russia
Tel: +7 (495) 783-26-80
Biocodex is an independent, family-owned French pharmaceutical company founded in 1953 by Michel Hublot and Francois Vallet.
We are present in more than 100 countries of the world through subsidiaries and partner companies.
We specialize in several therapeutic areas, namely:
– gastroenterology;
– neurology and psychiatry;
– pain treatment.
Our mission: to develop and make accessible to doctors and their patients effective and safe products which improve the health and quality of life of patients.
Biocodex in Russia
Biocodex drugs have been present in Russia since 1996.
In July 2008 the Biocodex company opened its representative office in Russia with head office in Moscow and 14 major cities covered.
Since 2009 the company promotes pharmaceuticals of a French ophthalmic company Laboratoires Thea, a European leader in the sphere of ophthalmology.
We specialize in several therapeutic areas, namely:
– gastroenterology;
– neurology and psychiatry;
– pain treatment.
You have been at your current position for less than a year, and joined BIOCODEX after having managed the Russian affiliate of Yves Saint Laurent. You have a long history…
IMEDA was founded in 2005, and today counts amongst its members 28 leading international companies in the Russian medical technology sector. What are the main goals of the association today,…
When we first met, you mentioned that you assumed this position in 2009, to help UCB Russia recover from a flat spin in the wake of the financial crisis. What…
Merck KGaA describes itself as the world’s oldest pharmaceutical and chemicals company. What is the company’s history here in Russia? The Russian subsidiary was actually incorporated over 100 years ago.…
Ipsen has recently announced the acquisition of a Russian pharmaceutical license. Even before this license, Russia was already one of the largest affiliates. of the group, as of 2010. The…
What were the difficulties in the CIS regions around the time of the financial crisis? Were there similarities to the situation in Russia? Yes, the situation in the CIS was…
You have been with Boehringer Ingelheim since the early days of your career in 1994. In the pharmaceutical sector, managers seem to jump from company to company quite often—but you…
You were the former director of RMBC, which was acquired in 2008 by the IMS. How important was this acquisition in terms of positioning the IMS on the Russian market?…
Roche is the leading company in the ONLS (high-technology reimbursement) segment of the prescription drug market, and also the top oncology company in Russia. As the General Manager of the…
You have been in Russia now for a bit less than a year, having come from the former Schering-Plough’s Hungary office to run the Russian MSD affiliate. In our conversation…
Binnopharm was established in 2006, with 100% of charter capital coming from holding company JSFC Sistema. What was the vision behind the creation of Binnopharm? The company was indeed established…
Nycomed is currently constructing a Greenfield plant in the Yaroslavl region, at an investment of 75-80Mn EUR. Last time we met in 2006, many foreign companies viewed local production as…
Celegene did not have a Russian affiliate office during Focus Reports’ initial report on Russia in 2006. What attracted Celgene’s relatively recent entrance into this market? We had external and…
See our Cookie Privacy Policy Here
